Erivedge (vismodegib) — Medica
Basal cell carcinoma, locally advanced
Initial criteria
- age ≥ 18 years
- EITHER (a) patient has recurrent basal cell carcinoma following surgery or radiation therapy OR (b) patient is not a candidate for surgery AND according to the prescriber, the patient is not a candidate for radiation therapy
Reauthorization criteria
- Patient is currently receiving Erivedge
Approval duration
1 year